Identifying therapeutic targets for Alzheimer's disease with big data

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Nilüfer Ertekin-Taner is a Professor of Neuroscience and Neurology at the Mayo Clinic, Jacksonville, FL, USA. A neurogeneticist and board-certified behavioral neurologist, she received her medical degree from Hacettepe University Medical School in Ankara, Turkey and her doctorate degree in Molecular Neuroscience from Mayo Graduate School. She completed her residency training in the Department of Neurology at Mayo Clinic in Rochester (MN, USA) and fellowship in Behavioral Neurology at Mayo Clinic in Jacksonville. Her laboratory aims to discover and characterize genetic factors underlying the complex genetics of Alzheimer's disease (AD) and related neurodegenerative conditions. Her earlier work contributed to the establishment of the endophenotype approach in genetic studies of AD and pioneered the use of amyloid β peptide levels as an endophenotype in AD genetic research. Her laboratory currently uses biological traits such as gene expression levels and cognitive scores and leverages combined genome, transcriptome and epigenetic data to uncover genetic risk factors for neurodegenerative conditions. She is the principal investigator of numerous NIH and foundation grants. She leads multiple collaborative projects aimed at gene and pathway discoveries in AD and other neurodegenerative diseases, as a part of the NIH initiatives Accelerating Medicines Partnership AD (AMP-AD) and Molecular Mechanisms of the Vascular Etiology of AD (M2OVE-AD) consortia. She is the Principal Investigator of the Florida Consortium for African-American AD Studies (FCA3DS). As a neurologist in the Memory Disorders Clinic at Mayo Clinic in Jacksonville, Florida, she continues to evaluate and manage patients with AD and other dementias and aspires to improve the quality of care that we provide to our patients and their families.

Original languageEnglish (US)
Pages (from-to)101-105
Number of pages5
JournalNeurodegenerative disease management
Volume7
Issue number2
DOIs
StatePublished - Apr 1 2017

Fingerprint

Alzheimer Disease
Neurology
Endophenotypes
Therapeutics
Neurosciences
Research Personnel
Genetic Research
Inborn Genetic Diseases
Organized Financing
Quality of Health Care
Memory Disorders
Genetic Association Studies
Internship and Residency
Turkey
Medical Schools
Transcriptome
Amyloid
Epigenomics
Neurodegenerative Diseases
African Americans

Keywords

  • Alzheimer's disease
  • big data
  • biomarker
  • genome
  • network analysis
  • prevention
  • therapeutic targets
  • transcriptome

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Identifying therapeutic targets for Alzheimer's disease with big data. / Taner, Nilufer.

In: Neurodegenerative disease management, Vol. 7, No. 2, 01.04.2017, p. 101-105.

Research output: Contribution to journalArticle

@article{29cf78798c20490a83cdff61e60809eb,
title = "Identifying therapeutic targets for Alzheimer's disease with big data",
abstract = "Nil{\"u}fer Ertekin-Taner is a Professor of Neuroscience and Neurology at the Mayo Clinic, Jacksonville, FL, USA. A neurogeneticist and board-certified behavioral neurologist, she received her medical degree from Hacettepe University Medical School in Ankara, Turkey and her doctorate degree in Molecular Neuroscience from Mayo Graduate School. She completed her residency training in the Department of Neurology at Mayo Clinic in Rochester (MN, USA) and fellowship in Behavioral Neurology at Mayo Clinic in Jacksonville. Her laboratory aims to discover and characterize genetic factors underlying the complex genetics of Alzheimer's disease (AD) and related neurodegenerative conditions. Her earlier work contributed to the establishment of the endophenotype approach in genetic studies of AD and pioneered the use of amyloid β peptide levels as an endophenotype in AD genetic research. Her laboratory currently uses biological traits such as gene expression levels and cognitive scores and leverages combined genome, transcriptome and epigenetic data to uncover genetic risk factors for neurodegenerative conditions. She is the principal investigator of numerous NIH and foundation grants. She leads multiple collaborative projects aimed at gene and pathway discoveries in AD and other neurodegenerative diseases, as a part of the NIH initiatives Accelerating Medicines Partnership AD (AMP-AD) and Molecular Mechanisms of the Vascular Etiology of AD (M2OVE-AD) consortia. She is the Principal Investigator of the Florida Consortium for African-American AD Studies (FCA3DS). As a neurologist in the Memory Disorders Clinic at Mayo Clinic in Jacksonville, Florida, she continues to evaluate and manage patients with AD and other dementias and aspires to improve the quality of care that we provide to our patients and their families.",
keywords = "Alzheimer's disease, big data, biomarker, genome, network analysis, prevention, therapeutic targets, transcriptome",
author = "Nilufer Taner",
year = "2017",
month = "4",
day = "1",
doi = "10.2217/nmt-2017-0008",
language = "English (US)",
volume = "7",
pages = "101--105",
journal = "Neurodegenerative disease management",
issn = "1758-2024",
publisher = "Future Medicine Ltd.",
number = "2",

}

TY - JOUR

T1 - Identifying therapeutic targets for Alzheimer's disease with big data

AU - Taner, Nilufer

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Nilüfer Ertekin-Taner is a Professor of Neuroscience and Neurology at the Mayo Clinic, Jacksonville, FL, USA. A neurogeneticist and board-certified behavioral neurologist, she received her medical degree from Hacettepe University Medical School in Ankara, Turkey and her doctorate degree in Molecular Neuroscience from Mayo Graduate School. She completed her residency training in the Department of Neurology at Mayo Clinic in Rochester (MN, USA) and fellowship in Behavioral Neurology at Mayo Clinic in Jacksonville. Her laboratory aims to discover and characterize genetic factors underlying the complex genetics of Alzheimer's disease (AD) and related neurodegenerative conditions. Her earlier work contributed to the establishment of the endophenotype approach in genetic studies of AD and pioneered the use of amyloid β peptide levels as an endophenotype in AD genetic research. Her laboratory currently uses biological traits such as gene expression levels and cognitive scores and leverages combined genome, transcriptome and epigenetic data to uncover genetic risk factors for neurodegenerative conditions. She is the principal investigator of numerous NIH and foundation grants. She leads multiple collaborative projects aimed at gene and pathway discoveries in AD and other neurodegenerative diseases, as a part of the NIH initiatives Accelerating Medicines Partnership AD (AMP-AD) and Molecular Mechanisms of the Vascular Etiology of AD (M2OVE-AD) consortia. She is the Principal Investigator of the Florida Consortium for African-American AD Studies (FCA3DS). As a neurologist in the Memory Disorders Clinic at Mayo Clinic in Jacksonville, Florida, she continues to evaluate and manage patients with AD and other dementias and aspires to improve the quality of care that we provide to our patients and their families.

AB - Nilüfer Ertekin-Taner is a Professor of Neuroscience and Neurology at the Mayo Clinic, Jacksonville, FL, USA. A neurogeneticist and board-certified behavioral neurologist, she received her medical degree from Hacettepe University Medical School in Ankara, Turkey and her doctorate degree in Molecular Neuroscience from Mayo Graduate School. She completed her residency training in the Department of Neurology at Mayo Clinic in Rochester (MN, USA) and fellowship in Behavioral Neurology at Mayo Clinic in Jacksonville. Her laboratory aims to discover and characterize genetic factors underlying the complex genetics of Alzheimer's disease (AD) and related neurodegenerative conditions. Her earlier work contributed to the establishment of the endophenotype approach in genetic studies of AD and pioneered the use of amyloid β peptide levels as an endophenotype in AD genetic research. Her laboratory currently uses biological traits such as gene expression levels and cognitive scores and leverages combined genome, transcriptome and epigenetic data to uncover genetic risk factors for neurodegenerative conditions. She is the principal investigator of numerous NIH and foundation grants. She leads multiple collaborative projects aimed at gene and pathway discoveries in AD and other neurodegenerative diseases, as a part of the NIH initiatives Accelerating Medicines Partnership AD (AMP-AD) and Molecular Mechanisms of the Vascular Etiology of AD (M2OVE-AD) consortia. She is the Principal Investigator of the Florida Consortium for African-American AD Studies (FCA3DS). As a neurologist in the Memory Disorders Clinic at Mayo Clinic in Jacksonville, Florida, she continues to evaluate and manage patients with AD and other dementias and aspires to improve the quality of care that we provide to our patients and their families.

KW - Alzheimer's disease

KW - big data

KW - biomarker

KW - genome

KW - network analysis

KW - prevention

KW - therapeutic targets

KW - transcriptome

UR - http://www.scopus.com/inward/record.url?scp=85060564391&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060564391&partnerID=8YFLogxK

U2 - 10.2217/nmt-2017-0008

DO - 10.2217/nmt-2017-0008

M3 - Article

C2 - 28540771

AN - SCOPUS:85060564391

VL - 7

SP - 101

EP - 105

JO - Neurodegenerative disease management

JF - Neurodegenerative disease management

SN - 1758-2024

IS - 2

ER -